Research on KRAS molecular glues is advancing, with a focus on developing treatments that can target specific mutations and interactions. The development of these treatments is driven by the need to address the challenges posed by KRAS mutations in cancer. Studies are exploring various approaches, including targeting specific KRAS mutations, such as G12C, and investigating new ways to interact with previously difficult-to-target molecules.